# A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

> **NCT05942508** · PHASE1 · UNKNOWN · sponsor: **Jinming Yu** · enrollment: 20 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer
- Not Progressed After First-line Chemoradiotherapy

## Interventions

- **DRUG:** TQB2450 Injection + Anlotinib Hydrochloride Capsules

## Key facts

- **NCT ID:** NCT05942508
- **Lead sponsor:** Jinming Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-30
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942508, "A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05942508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*